refractory follicular lymphoma
Showing 1 - 25 of 28
Follicular Lymphoma, Refractory Follicular Lymphoma Trial (Tazverik (Tazemetostat))
Not yet recruiting
- Follicular Lymphoma
- Refractory Follicular Lymphoma
- Tazverik (Tazemetostat)
- (no location specified)
Oct 6, 2023
Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma Trial in United Kingdom (Epcoritamab, Lenalidomide, Rituximab)
Not yet recruiting
- Relapsed Follicular Lymphoma
- Refractory Follicular Lymphoma
- Epcoritamab
- +10 more
-
Aberdeen, United Kingdom
- +24 more
Apr 28, 2023
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in United States (Bendamustine
Suspended
- Grade 1 Follicular Lymphoma
- +4 more
- Bendamustine Hydrochloride
- +13 more
-
Anchorage, Alaska
- +422 more
Feb 2, 2023
Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,
Completed
- Grade 3a Follicular Lymphoma
- +9 more
- Laboratory Biomarker Analysis
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 31, 2023
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in
Suspended
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +7 more
- Venetoclax
- +3 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Jan 20, 2023
Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Boston (TAZEMETOSTAT, Zandelisib)
Not yet recruiting
- Relapsed Follicular Lymphoma
- Refractory Follicular Lymphoma
-
Boston, Massachusetts
- +1 more
Oct 28, 2022
Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Trial in Seattle (procedure, drug, biological, radiation)
Recruiting
- Acute Leukemia
- +18 more
- Allogeneic Hematopoietic Stem Cell Transplantation
- +8 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 26, 2022
Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL, Recurrent Follicular Lymphoma Trial in Seattle (Nivolumab)
Recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +17 more
- Nivolumab
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 16, 2022
Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma
Recruiting
- Anaplastic Large Cell Lymphoma
- +19 more
- Pembrolizumab
- Pralatrexate
-
Duarte, California
- +2 more
Aug 15, 2022
Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular
Recruiting
- Aggressive B-Cell Non-Hodgkin Lymphoma
- +19 more
- CD47 Antagonist ALX148
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 9, 2022
Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Duarte (Tazemetostat, Ublituximab, Umbralisib)
Not yet recruiting
- Recurrent Follicular Lymphoma
- Refractory Follicular Lymphoma
- Tazemetostat
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jul 31, 2022
Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Worldwide (Loncastuximab Tesirine, Idelalisib)
Active, not recruiting
- Relapsed Follicular Lymphoma
- Refractory Follicular Lymphoma
- Loncastuximab Tesirine
- Idelalisib
-
Las Vegas, Nevada
- +33 more
Jul 26, 2022
Recurrent DLBCL, Recurrent Follicular Lymphoma, Refractory DLBCL Trial in Seattle (Laboratory Biomarker Analysis, Pembrolizumab,
Active, not recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +3 more
- Laboratory Biomarker Analysis
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 20, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL Trial in Seattle (biological,
Recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +20 more
- Chimeric Antigen Receptor T-Cell Therapy
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 11, 2022
Post-Transplant Lymphoproliferative Disorder, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL Trial in Seattle
Not yet recruiting
- Post-Transplant Lymphoproliferative Disorder
- +10 more
- Loncastuximab Tesirine
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 6, 2022
Refractory Follicular Lymphoma, Relapsed Follicular Lymphoma Trial in Washington, Hackensack, Seattle (Ibrutinib, Venetoclax)
Recruiting
- Refractory Follicular Lymphoma
- Relapsed Follicular Lymphoma
-
Washington, District of Columbia
- +2 more
Jul 6, 2022
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Palo Alto (Ibrutinib, Radiation
Active, not recruiting
- Grade 1 Follicular Lymphoma
- +6 more
- Ibrutinib
- +2 more
-
Palo Alto, CaliforniaStanford University, School of Medicine
Jun 13, 2022
Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma Trial (Acalabrutinib,
Withdrawn
- Recurrent Follicular Lymphoma
- +8 more
- (no location specified)
Jun 2, 2022
Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent DLBCL Trial in Atlanta, Columbus (other, drug, biological)
Recruiting
- Grade 3a Follicular Lymphoma
- +14 more
- Laboratory Biomarker Analysis
- +2 more
-
Atlanta, Georgia
- +1 more
May 31, 2022
Blastoid Variant Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Follicular Lymphoma Trial in United
Active, not recruiting
- Blastoid Variant Mantle Cell Lymphoma
- +8 more
- Ibrutinib
- Laboratory Biomarker Analysis
-
Birmingham, Alabama
- +4 more
May 10, 2022
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, Grade 1 Follicular Lymphoma,
Active, not recruiting
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
- +11 more
- Lenalidomide
- +2 more
-
Atlanta, Georgia
- +1 more
Apr 18, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,
Suspended
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +23 more
- Lenalidomide
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Feb 23, 2022
Mantle Cell Lymphoma, Recurrent DLBCL, Recurrent Follicular Lymphoma Trial in Houston (procedure, drug, biological)
Completed
- Mantle Cell Lymphoma
- +6 more
- Autologous Hematopoietic Stem Cell Transplantation
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Jan 18, 2022
Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Sacramento (Bendamustine Hydrochloride, Brentuximab
Recruiting
- Recurrent Follicular Lymphoma
- Refractory Follicular Lymphoma
- Bendamustine Hydrochloride
- Brentuximab Vedotin
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Dec 17, 2021
Hematopoietic Cell Transplantation Recipient, Recurrent DLBCL, Recurrent Grade 1 Follicular Lymphoma Trial in Columbus
Active, not recruiting
- Hematopoietic Cell Transplantation Recipient
- +11 more
- Carmustine
- +5 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Sep 29, 2021